International Conference on Biologics and Biosimilars 2018

With less than 10 biosimilars approved by USFDA, the drug class is still ints infancy. However, market penetration rate is quite high with more biologic products going off patent. Amgen Inc.’s (AMGN) Amjevita, a biosimilar of AbbVie’s (ABBV) Humira (adalimumab) secured FDA approval in September 2016, but is yet to be marketed due to legal hurdles. Production bottlenecks are the second most obvious challenge since biosimilar manufacturing is complex, as the drugs are derived from living cells. This often leads to higher manufacturing costs and concerns about scalability potential of the manufactured biosimilars. Nevertheless, pricing is an important parameter requiring optimization. Pfizer Inc. (PFE) secured approval for Inflectra (infliximab-dyyb), its biosimilar of Johnson & Johnson’s (JNJ) Remicade, in April 2016. However, the price of Inflectra is only 15% lower than that of Remicade, and the much-anticipated launch dented the hopes of deep discounts from biosims. Generics usually cost 80% less than branded drugs.

With so many challenges in research , still class of drug is experienceing the maximum funding with great Retuns on Investment(ROI). Keeping these points in mind we are organizng the 13th International Conference on Biologics and Biosimilars during October 24-25, 2018 at Boston, USA with the theme: Emerging Trends in Biosimilars Approvals, Market and Pricing.